Related Experiment Video

Updated: Feb 23, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

754

Vitamin D receptor gene polymorphisms in association with diabetic nephropathy: a systematic review and meta-analysis

Lina Yang1,2, Lan Wu1, Yi Fan2

  • 1Department of Geriatrics, the First Affiliated Hospital of China Medical University, 155th Nanjing North Street, Shenyang, Liaoning, 110001, People's Republic of China.

BMC Medical Genetics
|August 31, 2017
PubMed
Abstract

Insights

Vitamin D receptor (VDR) gene polymorphisms show no consistent link to diabetic nephropathy (DN) risk in diabetes mellitus (DM) patients. However, TaqI variants may increase DN susceptibility in Asian populations.

Area of Science:

  • Genetics
  • Endocrinology
  • Nephrology

Background:

  • Vitamin D receptor (VDR) gene polymorphisms are investigated for their association with diabetic nephropathy (DN) risk in diabetes mellitus (DM) patients.
  • Existing research presents inconclusive and inconsistent findings regarding this association.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the association between VDR gene polymorphisms (ApaI, BsmI, FokI, TaqI) and DN risk.
  • To clarify the inconsistent results from previous studies.

Main Methods:

  • A systematic literature search was performed across PubMed, Embase, Chinese National Knowledge Infrastructure, and Chinese Wanfang databases up to May 2016.
  • Seven studies with 2564 participants were included to analyze genotypic and allelic differences between DN patients and DM controls.

Main Results:

  • Overall analysis revealed no significant association between ApaI, BsmI, FokI, and TaqI VDR gene polymorphisms and DN susceptibility in diabetic patients (all P > 0.05).
  • Stratified analysis indicated that the TT genotype of TaqI variants was associated with increased DN susceptibility in Asian individuals (OR = 2.21, P = 0.04).
  • Sensitivity analyses confirmed the reliability of the results across overall populations, Caucasians, and Asians.

Conclusions:

  • No significant association was found between ApaI, BsmI, FokI, and TaqI polymorphisms and DN risk in the general population.
  • TaqI gene variants may be associated with DN susceptibility specifically in Asian populations.
  • Further research is warranted to validate these findings from the meta-analysis.
Keywords:
Diabetic nephropathyGene polymorphismsMeta-analysisVitamin D receptor

More Related Videos

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.7K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1000

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
32
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
4.3K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29